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Abstract 
 
Given the heterogeneous nature of FTD, sensitive biomarkers are in great need for the 
accurate diagnosis of this neurodegenerative disorder. Circulating miRNAs have been 
reported as promising biomarkers for neurodegenerative disorders and processes affecting the 
central nervous system, especially in aging. The objective of the study was to evaluate if some 
circulating miRNAs linked with apoptosis (miR-29b-3p, miR-34a-5p, miR-16-5p, miR-17-5p, 
miR-107, miR-19b-3p, let-7b-5p, miR-26b-5p and 127-3p) were able to distinguish between 
FTD patients and healthy controls. For this study, we enrolled 127 subjects, including 54 
patients with FTD, 20 patients with AD and 53 healthy controls. The qRT-PCR analysis 
showed a down-regulation of miR-127-3p in FTD compared to controls, while the levels of 
other miRNAs remained unchanged. Then, miR-127-3p expression was also analysed in AD 
patients, finding a different expression between two patient groups. A receiver operating 
characteristic (ROC) curve was then created for miR-127-3p to discriminate FTD versus AD 
(AUC: 0.8986), and versus healthy controls (AUC: 0.8057). In conclusion, miR-127-3p could 
help to diagnose FTD and to distinguish it from AD. 
 
Keywords: Frontotemporal dementia, miR-127-3p, differential diagnosis, biomarker, 
miRNA.  
 
Introduction 
Frontotemporal lobar degeneration (FTLD) is a neurodegenerative syndrome characterized by 
atrophy in the frontal and temporal lobes of the brain [1,2]. The disorder is the third most 
common dementia subtype with a prevalence ranging from 3% to 26% [3]. Clinically, patients 
show with either changes in behaviour and personality (behavioural variant FTD, bvFTD), or 
language impairment (primary progressive aphasia, PPA). PPA can be further divided into 
two main subtypes, semantic variant (svPPA) and non-fluent variant (nfvPPA) [4]. Moreover, 
different mutations have been found in genes such as those encoding Microtubule Associated 
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Protein Tau (MAPT), Progranulin (GRN), Chromosome 9 open reading frame 72 
(C9ORF72), TAR DNA-binding protein 43 (TDP-43), Fused in Sarcoma binding protein 
(FUS), Valosin-Containing Protein (VCP), Charged Multivesicular Body Protein 2B 
(CHMP2B) [5] and, recently, TANK-binding kinase 1 [6]. 
The diagnosis of the FTD spectrum of diseases is based on clinical symptoms. This hampers 
the differentiation of the diseases among each other and with other disorders that show a 
similar clinical appearance resulting in a high rate of misdiagnoses, so that a total of 10-30% 
of patients presenting with an FTD clinical syndrome are found to have Alzheimer’s disease 
on autopsy [7]. 
Accurate diagnosis is important for early and correct treatment of the diseases and for drug 
development. Great efforts have been made in the past to identify biomarkers especially in the 
CSF to improve differential diagnosis of FTD [8], but only a few potential biomarker 
candidates have been described in recent years. In this scenario, new biomarkers for FTD are 
needed to improve differential diagnosis within the disease spectrum and for related 
neurodegenerative diseases such as AD. 
Notably, circulating miRNAs have been reported as promising biomarkers for 
neurodegenerative disorders and processes affecting the central nervous system, especially in 
aging [9,10]. 
Different studies showed that miRNAs are playing an important role in FTD pathology 
[11,12]. For example, several reports have evaluated miRNAs regulation of the progranulin 
gene, suggesting that it is under their control, as described for miR-29b, miR-107 and miR-
659 [13–15].  
Apoptosis appears to play a key role in the progression of several neurologic disorders as 
demonstrated by studies on animal models and cell lines [16,17]. Brains of patients with 
neurodegenerative diseases are usually associated with significant cell loss accompanied by 
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typical morphological features of apoptosis such as chromatin condensation, DNA 
fragmentation, and activation of cysteine-proteases [18]. To date, we know from literature 
that miR-29b-3p, miR-34a-3p,miR-16-5p, miR-17-5p, mir-107,miR-19b-3p, let-7b-5p and 
miR-127-3p mediate apoptosis induced by hypoxic/ischemic or spinal cord injury. Moreover, 
miR-26b causes activation of cyclin-dependent kinase 5 and increase tau phosphorylation, 
followed by apoptosis and neurodegeneration. Therefore, we wondered whether the levels of 
these miRNAs were abnormal in the plasma of patients with frontotemporal dementia [19–
41]. To search for novel plasma miRNA signatures that can distinguish patients from healthy 
individuals, we selected nine miRNAs (miR-29b-3p, miR-34a-5p, miR-16-5p, miR-17-5p, 
miR-107, miR-19b-3p, let-7b-5p, miR-26b-5p and miR-127-3p), which have been reported to 
be closely correlated with apoptosis and/or dementia. 
 
 
 
Materials and Methods 
Patient recruitment and clinical evaluation 
Subjects were recruited consecutively at the Memory Clinic of  University “Sapienza” (Rome, 
Italy), and at the Alzheimer’s Unit of IRCCS Neuromed (Pozzilli, Italy).  
The study was approved by the Institutional Review Board of all centers and a written 
informed consent approved by the ethics committees was obtained from all participants 
involved in this study. The clinical diagnosis of probable FTD was defined according to 
current consensus criteria [42,43]. The clinical diagnosis of probable AD was defined 
according to the DSM-IV and Alzheimer’s disease and Related Disorders Association 
(NINCDS-ADRDA) criteria [44] in a consensus diagnostic conference by a panel of 
neurologists and neuropsychologists. The healthy control groups (Ctrl) were enrolled among 
healthy volunteers: family members or caregivers unrelated to the patients, all undergoing a 
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clinical interview with a neurologist with a completely normal cognitive and functional 
assessment. Moreover, all patients underwent standard evaluations that included I) a detailed 
clinical history recorded from the patients and/or caregivers; II) an extensive physical exam; 
III) neurological examination; IV) an extensive neuropsychological testing including the Mini 
Mental State Examination (MMSE); V) laboratory tests to exclude secondary causes of 
dementia; VI) brain imaging (magnetic resonance imaging or computerized tomography) and 
VII) in the most cases, 99mTc-HMPAO SPECT or FDG PET scan. Healthy subjects 
underwent clinical and neurological assessment including the administration of MMSE. All 
FTD patients were screened for possible mutations in MAPT, GRN and C9ORF72 genes. 
 
 
 
RNA isolation from plasma. 
Whole blood was recovered in tubes treated with EDTA and centrifuged for 15 min at 2500 
rpm at 4°C. Plasma layer was carefully collected without shaking the buffy coat. Total RNA 
was extracted from 250 µL of plasma using a miRNeasy mini kit (Qiagen), following the 
manufacturer’s recommendations. 1µg of MS2 bacteriophage RNA (Roche Diagnostics) was 
added to each sample to improve endogenous RNA recovery. Qubit RNA HS Assay Kit 
(Thermo Fisher Scientific) was used with the Qubit Fluorometer, to provide an accurate 
method for the quantification of low-abundance RNA samples. Evaluation of possible 
hemolysis contamination was carried out by comparing the level of a miRNA highly 
expressed in red blood cells (hsa-miR-451a), with a miRNA unaffected by hemolysis (hsa-
miR-23a-3p) [45]. ΔCt (miR-23a-3p - miR- 451a) gives a measure of hemolysis degree: ΔCt 
values of more than five indicate a possible erythrocyte miRNA contamination, and values of 
7–8 or more a high risk of hemolysis. 
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miRNA Reverse Transcription and quantitative Real Time PCR (qRT-PCR). 
80 ng of extracted RNA were retro-transcribed using Universal cDNA Synthesis kit (Exiqon) 
according to the manufacturer’s protocol. cDNA template was then diluted 50X in nuclease 
free water and mixed 1:1 with 2X PCR Master Mix (Exiqon). For miRNA quantitative PCR 
assays, samples were analysed in triplicates using miRCURY LNATM PCR primers set 
(Exiqon): hsa-miR-127-3p, hsa-miR-29b-3p, hsa-miR-191-5p, hsa-let-7d-5p, hsa-miR-107, 
hsa-miR-132 and endogenous control hsa-miR-93-5p. qRT-PCR reactions were performed 
using ExiLENT SYBR® Green master mix (Exiqon) in a CFX384 Real-Time PCR Detection 
System (Bio-Rad Laboratories). 10 µl PCR reaction contained 2 µl of the 1:80 diluted cDNA 
template, 5 µl of SYBR® Green master mix and 1 µl of PCR primer mix. The reaction 
protocol was as follows: 95°C for 10 minutes, followed by 40 amplification cycles of 95°C 
for 10 seconds and 60°C for 1 minute. Raw Ct values were normalized using the ΔCt method 
with respect to the endogenous control. In order to select the endogenous control, we tested 
five miRNAs as reference genes (hsa-miR-93-5p, hsa-miR-103, hsa-miR-191, hsa-miR-423-
3p, and hsa-miR-425-5p) checking their expression levels and stability in our samples by 
using Normfinder and Genorm software [46,47]. 
 
 
Statistical analysis 
Continuous data are summarized by mean and standard error, or median and interquartile 
range. Categorical variables are described by frequency and percentage distributions. 
Comparisons between experimental groups were assessed by the t-test or Mann-Whitney test 
for continuous variables, and by Fisher’s exact probability test and Pearson’s chi-square test 
for categorical variables. Spearman’s rank correlation coefficient was used to investigate 
association between continuous variables. 
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The effectiveness of ΔCt in discriminating between groups was assessed by the Receiver 
Operating Characteristic (ROC) curve analyses. Non-parametric ROC curves were obtained 
for FTD vs Ctrl and FTD vs AD. The area under the ROC curve (AUC) and its 95% 
confidence interval (95% CI) were calculated as a measure of diagnostic accuracy. Cut-points 
for ΔCt with fixed sensitivity and specificity were obtained from analysis of the ROC curve. 
The level of significance was 0.05 and Bonferroni’s correction was adopted to control for 
type I error in multiple comparisons. All statistical analyses were carried out by the software 
STATA 13 (StataCorpLP). 
 
Results 
127 subjects were enrolled in our study, including 54 probable FTD patients (31 bvFTD and 
23 PPA), 20 AD patients and 53 Ctrl. Patient and Ctrl characteristics are summarized in Table 
1. All patients had a MMSE ranging from 10 to 24. 
All patients were sporadic and no mutations were found in the most genes involved in FTD, 
MAPT, GRN and C9ORF72. Before the qRT-PCR, we verified possible cellular and 
haemolysis contamination and to minimize the carry-over of inhibitors into the RNA samples 
monitoring sample quality, in order to successfully analyse miRNAs expression. Then, we 
selected and tested five miRNAs as reference genes (hsa-miR-93-5p, hsa-miR-103, hsa-miR-
191, hsa-miR-423-3p, and hsa-miR-425-5p). We checked their expression levels and stability 
in our samples by using Normfinder and Genorm software, showing that miR-93-5p is the 
most highly expressed and stable among the five selected miRNAs (Supplementary Figure 1). 
miR-29b, miR-34a, miR-16-5p, miR-17-5p, miR-107, miR-19, let-7b, miR-26b and miR-127-
3p were screened by qRT-PCR, as possible candidate miRNAs able to discriminate FTD from 
cognitively healthy controls. The analysis showed the down-regulation of miR-127-3p in FTD 
respect to Ctrl (0.017±0.003 vs 0.058±0.007 p<0.0001) (Fig. 1 and Table 2). The other 
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analyzed miRNAs did not show significant difference in FTD with respect to Ctrl 
(Supplementary Figure 2). 
miR-127-3p expression was also analysed in patients with AD, finding a different expression 
between them (FTD 0.017±0.003 vs AD 0.078±0.014 p<0.0001). Moreover, an up-regulation 
of miR-127-3p was observed in AD subjects with respect to Ctrl, close to significance (AD 
0.078±0.014 vs Ctrl 0.058±0.007 p= 0.18) (Fig. 1 and Table 2). 
When all subjects were stratified on subgroups by gender, we found that significant 
differences of miR-127-3p levels between FTD and Ctrl, and between FTD and AD were 
observed both in males and in females (Fig. 2).  
Diagnostic accuracy of miR-127-3p expression levels was measured by AUC (95% CI) of 
ROC curves. AUC to discriminate FTD was 0.8057 (0.7242-0.8872) versus Ctrl (Fig. 3A) and 
0.8986 (0.8275-0.9697) versus AD (Fig.3B). The optimal cut-off values for detecting FTD vs 
Ctrl were selected. When the relative miR-127-3p value is under ΔCt 5.5, the sensitivity was 
81.48% and the specificity was 69.81%. Moreover, the optimal cut-off values for detecting 
FTD vs AD were selected, as well. When the relative miR-127-3p value is under ΔCt 5.5, the 
sensitivity was 81.48% and the specificity was 80.00% (Table 3). As the box-plot in Fig. 1 
shows some outliers, we tried to analyze diagnostic accuracy of miR-127-3p excluding them. 
We observed an AUC of 0.8382 (0.7602-0.9163) for FTD vs Ctrl and 0.9361 (0.8788-0.9934) 
for FTD vs AD (Supplementary Figure 3). 
When distinguished by gender, AUCs of miR-127-3p value to discriminate FTD versus Ctrl 
was 0.7684 in male (Fig. 4A) and 0.8264 in female (Fig. 4B) and to discriminate FTD versus 
AD was 0.9263 in males (Fig. 4C) and 0.8714 in females (Fig. 4D). 
 
Correlation of miR-127-3p level with clinical scores 
 The lag from disease onset to evaluation [median (IQR): 4.5 (4) and 4 (4), for FTD and AD 
respectively] did not differ among FTD and AD patients (Mann Whitney test, p=0.9363). 
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Moreover, there was no correlation between age at onset and lag from disease onset to 
evaluation (spearman’s rank correlation coefficient (p-value): -0.2243 (p=0.1030) and -0.16 
(p=0.4939) in FTD and AD respectively. Furthermore, miR-127-3p levels were not associated 
to lag from disease onset to evaluation both in FTD and in AD patients [Spearman’s rank 
correlation coefficient (p-value): -0.0734 (p=0.5981) and -0.3810 (p=0.0974), in FTD and AD 
respectively]. MMSE at evaluation was available for 51 of 54 FTD patients and for all AD 
patients. It did not differ among FTD and AD patients [median (IQR): 22 (13) and 18.5 (10.5) 
for FTD and AD respectively; Mann Whitney, p=0.0920)]. miR-127-3p levels were not 
associated with MMSE both in FTD and in AD patients (Spearman’s rank correlation 
coefficient (p-value): -0.0823 (p=0.5698) and -0.1198 (p=0.6148). 
 
Discussion 
Difficulties in accurate diagnosis of FTD require sensitive biomarkers support given the 
heterogeneous nature of the disorder. Great efforts to identify these biomarkers have been 
made over the past two decades, with a predominant focus on fluid biomaterial and 
neuroimaging features. In FTD, diagnostic biomarkers should discriminate among individuals 
with FTD, healthy subjects and individuals with other neurodegenerative diseases, and/or 
should differentiate among clinical, genetic or pathological subtypes. Staging biomarkers 
should enable us to assess disease severity and to discriminate between presymptomatic, 
prodromal, and early or late symptomatic stages of the disease.  
In this work, we propose a new biomarker, miR-127-3p, useful to improve the diagnosis of 
FTD. This is the first study demonstrating the dysregulation of miR-127-3p in plasma of 
patients with FTD. Although miR-127-3p is mainly known for its role in tumor diseases 
[48,49], experimental data show that it affects the induction of neuronal apoptosis by 
regulating the expression of mitoNEET, an iron-sulfur cluster transfer protein that binds to the 
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mitochondrial outer membrane [38]. In the central nervous system, miR-127-3p has been also 
described as a neuron-enriched miRNA playing a central role in neuronal differentiation 
[50,51]. 
Other authors have shown that the down-regulation of miR-127 in rat liver cells promotes cell 
proliferation, while its up-regulation inhibits proliferation [52]. 
These observations suggest an important role for this miRNA in cell proliferation, 
differentiation, and development. Chen and colleagues observed that miR-127 induces 
senescence in human fibroblasts and inhibits the proliferation of breast cancer cells by 
targeting the oncogene BCL6; they suggest miR-127 as a novel senescence-associated (SA)-
miRNA regulating cellular senescence [53]. 
Recently, miR-127-3p has also been considered a possible biomarker of different 
neurodegenerative diseases. Burgos and colleagues, profiling miRNAs content in CSF and 
serum by Next Generation Sequencing (NGS), found miR-127-3p up-regulated in AD serum 
and down-regulated in AD CSF when compared to neurologically normal age-matched 
controls. Moreover, miR-127-3p was also found down-regulated in CSF of PD patients 
compared with control subjects [54]. In our study on plasma, we observed a similar trend to 
Burgos’ serum data, but the statistical analysis resulted not significant (p= 0.18). Other 
authors have detected miR-127 involvement in other Neurodegenerative Diseases (NDs), such 
as Multiple Sclerosis (MS). Small RNA NGS was performed to profile exosome-associated 
miRNAs in serum samples from MS patients and healthy controls. They identified 
differentially expressed exosomal miRNAs in both relapsing-remitting MS (RRMS) and 
progressive MS patient sera in relation to controls. miR-127-3p was found up-regulated in 
progressive MS patients with respect to controls [55]. 
In our study, we show that expression levels of miR-127-3p were lower in plasma from FTD 
patients compared to subjects with AD. Several works attempted to identify miRNAs, as 
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useful candidates in the clinical differential diagnosis of dementia particularly for AD. A 
recent study investigated miRNAs expression patterns in patients diagnosed with AD and 
patients diagnosed with either vascular dementia, frontotemporal dementia or dementia with 
Lewy bodies. They found that miR-29c-3p and miR-15a-5p had the highest classification 
accuracies separately, and by combing them in a simple ratio model (RELmiR-29c-
3p/RELmiR-15a-5p), they found that AD patients could be distinguished from patients with 
other types of dementia (cut-off value 0.92) with a sensitivity of 90% and a specificity of 
100% [56]. In another work investigating the assessment of circulating brain-enriched 
miRNAs as potential biomarkers for AD, FTD, PD, and amyotrophic lateral sclerosis (ALS), 
the authors revealed miRNA classifiers capable of differentiating NDs from each other with 
accuracy ranging from 0.77 (AUC, 0.87) for AD vs FTD to 0.93 (AUC, 0.98) for AD vs ALS 
[57]. Moreover, Vallelunga and colleagues, identified three up-regulated miRNAs in serum of 
MSA patients (miR-24, miR-34b, miR-148b) in comparison to PD patients [58]. 
By analysing all subjects on subgroups characterized by gender, we found that miR-127-3p is 
differential expressed in FTD in both males and females. We chose to extend the analysis by 
gender considering that miR-127-3p is regulatedby estrogen related receptor gamma (ERRc) 
[59]. Actually, recent studies suggest that the regulation of miRNA expression levels might be 
influenced by hormonal and genetic background [60]. Ziats and colleagues evaluated the 
gender-dependent miRNA expression in the prefrontal cortex of human brain. They 
discovered 40 miRNAs with significant expression differences between the prefrontal cortex 
of males and females. Strikingly, 93% were more highly expressed in females [61]. Several 
studies showed sex differences in miRNAs expression in patients with neurological diseases. 
Sheinerman and colleagues revealed sex dependence of certain brain-enriched miRNAs, 
which distinguished NDs from HC in sex-specific subsets with a significantly higher accuracy 
than in the total (female and male) population [57]. In another study, Denk and colleagues 
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described gender specific differences concerning miR-106a, miR-17, miR-320, miR-19a, 
miR-221, miR-532, miR-95 in CSF of AD patients [62]. Moreover, miR-30b, regulated by 
estrogens, was observed to be significantly down-regulated in female schizophrenic brains 
with respect to males [63]. Then, not considering possible differences between males and 
females in miRNA and, in general, in biomarker analysis could introduce a gender-bias in the 
study[64]. 
Few literatures exist on role of miR-127 in brain, so that speculating about a disease-specific 
pathogenic mechanism that could explain differences between AD and FTD is not possible. 
Additional studies exploring a potential biological function of this miRNA circulating in body 
fluids are required. 
A limit of the study is the lack of a MCI population to investigate miR-127 as biomarker for 
early diagnosis in a longitudinal study. The cohort Studies of Memory in an International 
Consortium (COSMIC) estimated MCI prevalence to be 5.9% in people 60 years and older 
[65]. The annual rate in which MCI progresses to dementia was 9.6% [66], even if an overall 
18% reversion rate from MCI to NC was calculated, as well [67]. In those MCI cases destined 
to develop a dementia, biomarkers are emerging to help identify etiology and predict 
progression. In fact, subjects with MCI could benefit from early diagnosis and consequently 
potential treatment options, thus delaying their evolution and improving their quality of life 
and that of their relatives [68]. 
 
In conclusion, we show that expression levels of miR-127-3p were decreased in plasma from 
FTD patients compared to healthy subjects and patients with AD, suggesting that miR-127-3p 
could help to diagnose FTD and to distinguish it from AD. 
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Figure legends 
 
 
Figure 1. Box plots show the distribution of miR-127-3p values in AD (n=20), Ctrl 
(n=53) and FTD (n=54) subjects.  
The line in the middle of the box represents the median. The box extends from the 25th 
percentile (x[25]) to the 75th percentile (x[75]), the so-called interquartile range (IQ). The 
lines emerging from the box extend to the upper and lower adjacent values. The upper 
adjacent value is defined as the largest data point less than or equal to x[75] + 1.5 IQ. The 
lower adjacent value is the smallest data point greater than or equal to x[25] - 1.5 IQ. Dots 
indicate observed data points more extreme than the adjacent values (referred to as outliers). 
 
Figure 2. Scatter plots of miR-127-3p expression levels in FTD vs Ctrl and in FTD vs AD 
in males and females. 
 
Figure 3. ROC curves of miR-127-3p. 
Receiver operating characteristic curve of differentially expressed miR-127-3p in A) FTD vs 
Ctrl and B) FTD vs AD. 
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Table 1. Demographic and clinical features of subjects in the study 
 
 Ctrl 
(n=53) AD (n=20) 
FTD 
(n=54) 
AD vs 
Ctrl 
FTD vs 
Ctrl FTD vs AD 
F (%) 33 (62) 10 (50) 35 (65) 
0.5041(Overall) 
M (%) 20 (38) 10 (50) 19 (35) 
Age at evaluation  
Mean (SE) 71.6 (1.0) 71.3 (1.8) 70.3 (1.2) 0.8844
2 0.38772 0.63072 
MMSE 
Median (IQR) 
 18.5 (10.5) 22 (13)   ns (0.0920) 
Disease duration 
at evaluation 
Median (IQR) 
 
4.5 (4) 4 (4)   ns 
 
 
1: Fisher’s exact probability test 
2: t-test 
 
 
Table 2. Comparisons among groups (Ctrl, AD and FTD) of miR-127-3p levels 
The table shows the number of subjects in each group, the average raw 2-ΔCt and standard 
error of miR-127-3p levels, and p value for each comparison. 
 
2-ΔCt 
Mean (SE) p value 
Ctrl (n=53) AD (n=20) FTD (n=54) AD vs Ctrl FTD vs Ctrl FTD vs AD 
0.058 
(0.007) 0.078 (0.014) 0.017 (0.003) 0.1796 <0.0001 <0.0001 
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Table 3.Accuracy of ΔCT criteria by study population 
 
 
 
 
 
 
Figure 1 
 
 
 
 
  
    AD vs FTD Ctrl vs FTD  
Cutpoint ΔCt 
2-
ΔCt 
 Sensitivity Specificity Correctly Classified LR+ LR- Sensitivity Specificity Correctly Classified LR+ LR- 
( >= 3.395 ) 3.40 0.10  100.00% 35.00% 82.43% 1.5385 0 100.00% 20.75% 60.75% 1.2619 0 
( >= 4.255 ) 4.26 0.05  90.74% 55.00% 81.08% 2.0165 0.1684 90.74% 35.85% 63.55% 1.4145 0.2583 
( >= 5.495 ) 5.50 0.02  81.48% 80.00% 81.08% 4.0741 0.2315 81.48% 69.81% 75.70% 2.6991 0.2653 
( >= 5.94 )  5.94 0.02  70.37% 90.00% 75.68% 7.037 0.3292 70.37% 77.36% 73.83% 3.108 0.383 
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Figure 3 
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Figure 4 
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Supplementary Material 
 
 
Supplementary Figure 1. Scatter plots of reference genes selected to normalize analyzed miRNAs. 
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Supplementary Figure 2. Scatter plots of miR-29b-3p, miR-34a-5p, miR-16-5p, miR-17-5p, miR-107, miR-
19b-3p, let-7b-5p and miR-26b-5p in Ctrl vs FTD patients. 
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Supplementary Figure 3 
 
ROC curves of miR-127-3p for FTD vs Ctrl (A) and FTD vs AD (B) excluding outliers identified in box 
plots. 
 
 
 
